- 01Nexsen-FlashDx form 50:50 JV for enhanced GBS test.
- 02Nexsen adds sample-prep boost; FDA 510(k) & EU IVDR.
- 03APAC focus: HK first; India potential.
Nexsen Limited (ASX: NXN) has entered a non-binding term sheet with FlashDx Shenzhen to establish a 50:50 joint venture focused on developing and commercialising an enhanced molecular Group B Streptococcus (GBS) diagnostic.
The proposed JV would build on FlashDx’s existing CE-marked molecular GBS test, combining its established technology and manufacturing capability with a Nexsen-developed sample-preparation enhancement intended to improve detection at low bacterial levels.
Nexsen would lead and fund agreed regulatory work for the enhanced product, including planned US Food and Drug Administration 510(k) clearance and conformity under the European Union In Vitro Diagnostic Medical Devices Regulation.
The partners are targeting near-term market entry across Asia-Pacific, with Hong Kong expected to be an initial focus and India identified as another priority market subject to its applicable regulatory pathway.
The molecular product is intended for hospital and intrapartum testing and would sit alongside Nexsen’s separate StrepSure rapid lateral-flow program for antenatal screening and decentralised care.
Enclosed Molecular System
FlashDx’s existing GBS test uses an enclosed sample-to-answer molecular system to detect the bacteria from vaginal swab samples, with results available in under one hour and built-in quality control.
Nexsen plans to contribute sample-preparation technology designed to release more GBS material from each sample before testing, with the aim of making lower bacterial levels easier for the molecular test to detect.
The two GBS products are designed to address different clinical settings, workflows and price points, with GBS carried by about 10% to 30% of pregnant women across roughly 132 million births globally each year.
“The proposed joint venture with FlashDx has the potential to materially accelerate Nexsen’s commercial strategy—we have built strong hospital, clinical and commercial relationships across Asia-Pacific, and FlashDx gives us the opportunity to combine that network with an established molecular technology that already underpins a CE-marked GBS diagnostic,” managing director Mark Muzzin said.
“Nexsen is also bringing its own technical contribution to the product, including an enhancement designed to improve detection where bacterial levels are low, giving us a much more advanced starting point than developing a molecular system from scratch, while still allowing us to build a product specifically for the regulatory and commercial pathways we are targeting.”
Joint Venture Structure
The term sheet contemplates a new company owned equally by Nexsen and FlashDx, with the parties also participating equally in profits generated by the proposed JV.
FlashDx would exclusively manufacture and supply the GBS test to the JV and, after the targeted regulatory approvals are obtained, transfer applicable cartridge-specific intellectual property while retaining ownership of its platform, device, reader, and manufacturing know-how.
The JV would hold regulatory data, submissions, and future intellectual property developed in connection with the GBS test, while three US clinical sites already engaged by Nexsen are intended to support the FDA program.
The parties currently anticipate Nexsen will lead sales and commercial development across Asia-Pacific markets outside China, drawing on research, clinical and commercial relationships established in Hong Kong, and through its partnership with Universiti Malaya.
The proposed JV remains subject to the parties agreeing a detailed business plan and binding transaction documents including shareholder, manufacturing, and supply arrangements, while planning for commercial entry as the US regulatory program begins.
Get the wire before the market opens.
The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.